engleski

Analytical issues in lipoprotein (a) determination and their impact on assessing the therapeutic effect

Lp(a) is recognized by professional associations such as ESC/EAS, HEART UK, EAS/EFLM (for LDLC correction) as a cardiovascular disease risk factor. Although Lp(a) molecules have a highly heterogeneous structure and the ratio of mass to molar concentration varies between individuals, recommendations present Lp(a) levels in different units and some additionally suggest arbitrary conversion coefficients. Furthermore, the analytical method and measuring system used can alter the follow-up of the applied therapeutic approach such as apheresis or innovative medications that selectively target Lp(a). The aim of this study was to compare Lp(a) results on two different analytical platforms.

Lipoprotein (a) ; atherosclerosis ; harmonization

nije evidentirano